ACSL4 and Alzheimer disease: However, across many checkpoint-focused AD studies that primarily target oxidative stress, Aβ clearance, or neuroinflammatory ‘checkpoints’, the field has only rarely measured a complete ferroptosis signature—that is, simultaneous assessment of iron-dependent lipid peroxidation together with GPX4/SLC7A11 and ACSL4/LPCAT3 alterations, combined with ferroptosis-selective rescue experiments (e.g., ferrostatin-1, liproxstatin-1, or FSP1 activation).